Search

Type

Audience

Category

Issue

Last updated

Please note: using the search filters may not provide accurate search results for records prior to November 2021. When searching for older records, please ensure that you use the include archive checkbox.

Displaying 1 - 1 of 1 items.

Health alert or recall RUZURGI (amifampridine) - Removal from Canadian Market: Options for Continued Treatment for Lambert-Eaton Myasthenic Syndrome
UPDATED INFORMATION - March 11, 2022 On March 10, 2022, for the second time, the Federal Court set aside Health Canada’s decision to authorize RUZURGI (amifampridine), and the second Notice of Compliance (NOC) that had been issued on June 24, 2021…
AlertHealth professional risk communication | 2022-03-11
Report a problem or mistake on this page
What was wrong?

You will not receive a reply. Telephone numbers and e-mail addresses will be removed.

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.